Q: What are some of the biggest challenges we need to overcome to drive the adoption of clinical genomics and realize the benefits of truly personalized medicine? What promises for improved outcomes for a patient can we expect in a more technologically advanced personalized health...
Q: In your roles as Assistant Vice Chancellor and Chief Information Officer of UCLA Health Sciences, you are responsible for the health information technology strategic plan. What emerging healthcare technologies do you anticipate will have the greatest impact on the strategic plan in the next...
Q: What are the overarching goals of the California Initiative to Advance Precision Medicine (CIAPM) and can you give us an idea of the types of demonstration projects you have undertaken? A: The goal of the Initiative is to maximize the use of the California’s enormous...
Q: Genomics, Digital Health, Big Data, and Artificial Intelligence are some of the newest technologies/fields that are reshaping medicine and healthcare. • How will these technologies impact healthcare, and in particular individualized medicine? • What can we realistically expect from these technologies to improve healthcare and in what...
Q: Genomics, Digital Health, Big Data, and Artificial Intelligence are some of the newest technologies/fields that are reshaping medicine and healthcare. • How will these technologies impact healthcare and in particular individualized medicine? • What is it that...
Q: Genomics, Digital Health, Big Data, and Artificial Intelligence are some of the newest technologies/fields that are reshaping medicine and healthcare. • How will these technologies impact healthcare and in particular individualized medicine? • What is it that...
Q: Immunotherapy is redefining how we treat cancer. How is this treatment approach impacting healthcare and in particular individualized medicine? A: Over the last couple of decades, we have been able to improve oncology treatment for late stage cancer patients. We have been able to...
Q: Severe combined immunodeficiency (SCID) is characterized by severely impaired T-cell development and is fatal without treatment. What is the current treatment of infants identified as having SCID, and what is their likely clinical outcome if treated shortly after birth? A: • Overall, with improvements in...
Q: Genomics, Digital Health, Big Data, and Artificial Intelligence are some of the newest technologies/fields that are reshaping medicine and healthcare. How will these technologies impact healthcare and in particular individualized medicine? Are we there yet in terms of tangible impact, or is a good...
Q: What does your role entail as the director of the MolDX program at Palmetto GBA? A: The job directing MolDX is multifaceted; first and foremost the MolDX program is responsible for assessing molecular diagnostic tests on the market and makes coverage and pricing determinations for...
